Revenio Group Corporation: Revenio to purchase it's own shares

Revenio Group Corporation, Stock Exchange Release, February 25, 2016 at 13:00

Revenio to purchase it's own shares

The Board of Directors of Revenio Group Corporation has today decided to begin purchasing the company's own shares. The maximum amount of 7,000 shares are to be bought on the grounds of the authorization given by the Annual General Meeting on March 19, 2015.

The shares will be purchased through public trading on the Nasdaq Helsinki at the market price prevailing at the time of purchase. The shares will be purchased and paid according to the rules of Nasdaq Helsinki and Euroclear Finland Oy.

The purchase of the Company's own shares will begin on February 29, 2016 at the earliest and it will continue until the abovementioned share amount is purchased or until March 14, 2016 at the latest.           

The purchasing of the shares is carried out from the invested unrestricted equity fund, by decreasing it.

Revenio Group Corporation
Board of Directors

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki.